Birchview Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Birchview Capital’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,000	Closed	-$227K	–	56
2018 Q2	$227K	Hold	5,000	–	–	0.15%	42
2018 Q1	$264K	Hold	5,000	–	–	0.17%	41
2017 Q4	$340K	Hold	5,000	–	–	0.2%	28
2017 Q3	$412K	Sell	5,000 -2,000	-29%	-$159K	0.21%	26
2017 Q2	$655K	Sell	7,000 -3,000	-30%	-$184K	0.35%	21
2017 Q1	$637K	Buy	+10,000	New	+$608K	0.35%	21

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Birchview Capital's CLVS Position: Q3 2018 in Review

Birchview Capital sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 5,000 shares — an estimated $227K sold.

Birchview Capital first reported a position in CLVS in Q1 2017 and held it in 6 quarters. The position peaked at $655K in Q2 2017. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

Birchview Capital reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
Birchview Capital sold 5,000 Clovis Oncology, Inc. shares in Q3 2018, an estimated $227K.
Birchview Capital first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 6 quarters.
Birchview Capital's Clovis Oncology, Inc. position peaked at $655K in Q2 2017.
192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Birchview Capital's 13F filing for Q3 2018, filed 1 Nov 2018.